Jessica Teeling, PhD, studied medical biology at the University of Amsterdam, Netherlands, followed by studies of immunology and hematology leading to the award of PhD. In 2001, she became a founding member of a biotech company called Genmab, where she developed a therapeutic antibody called ofatumumab, which was approved for the treatment of leukemia by the U.S. Food and Drug Administration (FDA) in 2009. In 2004, she became a staff member at the University of Southampton, and in 2008, she established her own research group to study inflammation in the aging brain and eye. In 2016, she received her chair in experimental neuroimmunology. Dr. Teeling's primary research interest is the role of the immune system in the onset and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Her research aims to develop antibody-mediated immunotherapies to treat neurodegenerative diseases, including engineered antibodies with improved ability to travel to the brain and/or altered effector function to slow disease progression.